Daniel James George

Journal Article Eur Urol · October 10, 2024 BACKGROUND AND OBJECTIVE: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Confe ... Full text Link to item Cite

Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy.

Journal Article Oncologist · October 3, 2024 BACKGROUND: Even though cytoreductive nephrectomy (CN) was once the standard of care for patients with advanced renal cell carcinoma (RCC), its role in treatment has not been well analyzed or defined in the era of immunotherapy (IO). MATERIALS AND METHODS: ... Full text Link to item Cite

Incentive Planning

Journal Article Clinical Advances in Hematology and Oncology · October 1, 2024 Cite

Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing.

Journal Article BMC Public Health · September 18, 2024 BACKGROUND: Black men consistently have higher rates of prostate cancer (PCA)- related mortality. Advances in PCA treatment, screening, and hereditary cancer assessment center around germline testing (GT). Of concern is the significant under-engagement of ... Full text Link to item Cite

Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.

Journal Article J Clin Oncol · September 10, 2024 Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Up ... Full text Link to item Cite

Systemic treatments for advanced prostate cancer: relationship between health insurance plan and treatment costs.

Journal Article Am J Manag Care · September 1, 2024 OBJECTIVES: The high costs of cancer care can cause significant harm to patients and society. Prostate cancer, the leading nonskin malignancy in men, is responsible for the second-highest out-of-pocket (OOP) payments among all malignancies. Multiple first- ... Full text Link to item Cite

Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).

Journal Article J Clin Oncol · August 10, 2024 PURPOSE: Bempegaldesleukin (BEMPEG) is a pegylated interleukin (IL)-2 cytokine prodrug engineered to provide controlled and sustained activation of the clinically validated IL-2 pathway, with the goal of preferentially activating and expanding effector CD8 ... Full text Link to item Cite

Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.

Journal Article Eur Urol Oncol · August 2024 BACKGROUND: In the HERO study, relugolix demonstrated sustained testosterone suppression superior to that of leuprolide acetate (97% vs 89%; difference 7.9% [95% confidence interval, 4.1-12%; p < 0.001]). OBJECTIVE: To analyze testosterone recovery in a pr ... Full text Link to item Cite

Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma.

Journal Article Eur Urol Open Sci · August 2024 INTRODUCTION AND HYPOTHESES: The Outcomes Database to prospectivelY aSSEss the changing TherapY landscape in Renal Cell Carcinoma (ODYSSEY RCC) Registry is a large, nationally representative prospective registry of patients with metastatic renal cell carci ... Full text Link to item Cite

Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.

Journal Article JAMA Netw Open · August 1, 2024 IMPORTANCE: Novel androgen receptor inhibitors (ARIs; darolutamide, enzalutamide, and apalutamide) are standard-of-care treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC). However, there are sparse data comparing their clinical use ... Full text Link to item Cite

Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale.

Journal Article Clin Genitourin Cancer · July 23, 2024 The clinical rationale for treatment of castration-sensitive prostate cancer (CSPC) with novel hormonal therapy (NHT) or androgen receptor pathway inhibitor is reviewed. A PubMed search was conducted to identify relevant publications on NHTs for CSPC treat ... Full text Link to item Cite

Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States.

Journal Article J Manag Care Spec Pharm · July 2024 BACKGROUND: The advent of next-generation imaging will likely reduce nonmetastatic prostate cancer (PC) prevalence and increase identification of metastatic prostate cancer cases, resulting in two predominant advanced stages in the metastatic setting. Ther ... Full text Link to item Cite

Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.

Journal Article JAMA Oncol · May 1, 2024 IMPORTANCE: Combination androgen deprivation therapy (ADT) with radiotherapy is commonly used for patients with localized and advanced prostate cancer. OBJECTIVE: To assess the efficacy and safety of the oral gonadotropin-releasing hormone antagonist relug ... Full text Link to item Cite

Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · April 2, 2024 BACKGROUND: Previous studies have shown that Black men receive worse prostate cancer care than White men. This has not been explored in metastatic castration-sensitive prostate cancer (mCSPC) in the current treatment era. METHODS: We evaluated treatment in ... Full text Link to item Cite

Empty Nest

Journal Article Clinical Advances in Hematology and Oncology · April 1, 2024 Cite

Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · March 27, 2024 BACKGROUND: There are no large head-to-head phase 3 clinical trials comparing overall survival (OS) for abiraterone and enzalutamide. This study used Medicare claims data to compare OS in patients with chemotherapy-naïve metastatic castration-resistant pro ... Full text Link to item Cite

The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.

Conference Clin Cancer Res · March 15, 2024 PURPOSE: HOXB13 is an androgen receptor (AR) coregulator specifically expressed in cells of prostatic lineage. We sought to associate circulating tumor cell (CTC) HOXB13 expression with outcomes in men with mCRPC treated with abiraterone or enzalutamide. E ... Full text Link to item Cite

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.

Journal Article Cancer Immunol Immunother · March 2, 2024 BACKGROUND: Inhibition of the adenosine 2A receptor (A2AR) diminishes the immunosuppressive effects of adenosine and may complement immune-targeting drugs. This phase 2 study evaluated the A2AR antagonist AZD4635 in combination with durvalumab or oleclumab ... Full text Link to item Cite

Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.

Journal Article Cancer Epidemiol Biomarkers Prev · March 1, 2024 BACKGROUND: Studies have shown improved survival among individuals with cancer with higher levels of social support. Few studies have investigated social support and overall survival (OS) in individuals with advanced prostate cancer in an international coh ... Full text Link to item Cite

Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · February 22, 2024 Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We pr ... Full text Link to item Cite

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.

Journal Article Prostate Cancer Prostatic Dis · February 12, 2024 BACKGROUND: CALGB 90401 (Alliance) was a phase III trial of 1050 patients with metastatic castration-resistant prostate cancer (mCRPC) comparing docetaxel, prednisone, bevacizumab (DP+B) versus DP alone. While this trial did not show an improvement in over ... Full text Link to item Cite

Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States.

Journal Article Cancer Res Commun · January 8, 2024 UNLABELLED: Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions of pain and the associati ... Full text Link to item Cite

Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal Article Br J Cancer · January 2024 BACKGROUND: CC-115, a dual mTORC1/2 and DNA-PK inhibitor, has promising antitumour activity when combined with androgen receptor (AR) inhibition in pre-clinical models. METHODS: Phase 1b multicentre trial evaluating enzalutamide with escalating doses of CC ... Full text Link to item Cite

Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation.

Journal Article J Med Econ · 2024 AIMS: To describe healthcare costs of patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1 L) therapies from a US payer perspective. METHODS: Patients initiating a Flatiron oncologist-defined 1 L mCRPC therapy (ind ... Full text Link to item Cite

Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States.

Journal Article J Med Econ · 2024 AIMS: To describe healthcare resource utilization (HRU) and costs of patients with metastatic castration-sensitive prostate cancer (mCSPC). METHODS: Linked data from Flatiron Metastatic PC Core Registry and Komodo's Healthcare Map were evaluated (01/2016-1 ... Full text Link to item Cite

Taking Leave

Journal Article Clinical Advances in Hematology and Oncology · January 1, 2024 Cite

Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race.

Journal Article Clinicoecon Outcomes Res · 2024 BACKGROUND: Alterations in DNA damage repair genes in advanced prostate cancer (PC) may impact responses to therapy and clinical outcomes. This study described homologous recombination repair (HRR) testing patterns and clinical outcomes among patients with ... Full text Link to item Cite

What's in a Name? Why Words Matter in Advanced Prostate Cancer

Journal Article European Urology · January 1, 2024 Full text Cite

Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.

Journal Article Clin Genitourin Cancer · December 2023 INTRODUCTION: Biomarkers are needed to identify patients with metastatic renal cell carcinoma (mRCC) most likely to benefit from immune checkpoint inhibitors. We examined associations between radiographically assessed body composition (BC) variables and bo ... Full text Link to item Cite

Breakthroughs in Cancer Care

Journal Article Clinical Advances in Hematology and Oncology · December 1, 2023 Cite

Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.

Journal Article Qual Life Res · November 2023 PURPOSE: To assess differences in baseline and longitudinal quality of life among Black and White individuals in the US with advanced prostate cancer. METHODS: Secondary analysis of data from the International Registry for Men with Advanced Prostate Cancer ... Full text Link to item Cite

Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UK.

Journal Article Patient · November 2023 BACKGROUND: Treatment options for patients with metastatic hormone-sensitive prostate cancer (mHSPC) have broadened, and treatment decisions can have a long-lasting impact on patients' quality of life. Data on patient preferences can improve therapeutic de ... Full text Link to item Cite

Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer.

Journal Article Cancers (Basel) · October 5, 2023 Background: Relugolix is an oral GnRH receptor antagonist approved for men with advanced prostate cancer. Relugolix treatment has demonstrated an ability to lower testosterone to sustained castration levels in the phase 4 HERO study. Herein, we describe th ... Full text Link to item Cite

Plain language summary: Does the amount of time it takes for prostate-specific antigen to double affect how long men with nonmetastatic castration-resistant prostate cancer live and their healthcare costs?

Journal Article Future Oncol · October 2023 WHAT IS THIS SUMMARY ABOUT?: This is a plain language summary of a research article originally published in Clinical Genitourinary Cancer. The original article described the effect of rapidly rising prostate-specific antigen (PSA) levels on how long men wi ... Full text Link to item Cite

Assessing the utility of molecular diagnostic classification for cancers of unknown primary.

Journal Article Cancer Med · October 2023 BACKGROUND: Roughly 5% of metastatic cancers present with uncertain origin, for which molecular classification could influence subsequent management; however, prior studies of molecular diagnostic classifiers have reported mixed results with regard to clin ... Full text Link to item Cite

Doctors Without Boundaries

Journal Article Clinical Advances in Hematology and Oncology · October 1, 2023 Cite

Experience with the US health care system for Black and White patients with advanced prostate cancer.

Journal Article Cancer · August 15, 2023 OBJECTIVE: The purpose of this study was to assess differences in reported information about treatment, integration into care, and respect by self-identified Black and White individuals with advanced prostate cancer in the United States. PATIENTS AND METHO ... Full text Link to item Cite

Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.

Journal Article Clin Genitourin Cancer · August 2023 INTRODUCTION: In patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), prostate-specific antigen doubling time (PSADT) is associated with risk of metastasis and survival. This study evaluated the association of PSADT with clinical and ... Full text Link to item Cite

Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial.

Journal Article JCO Precis Oncol · August 2023 PURPOSE: Men with rising prostate-specific antigen (PSA) after radical prostatectomy (RP) may progress despite radiation and androgen-deprivation therapy (ADT). Tissue-based transcriptomic signatures can identify who may benefit from a more aggressive syst ... Full text Link to item Cite

Dog Traits

Journal Article Clinical Advances in Hematology and Oncology · August 1, 2023 Cite

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen.

Journal Article World J Mens Health · July 2023 PURPOSE: Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need to optimize practices to better risk-stratify patients. We examined initial longitudinal outcomes of mid-life men with an elev ... Full text Link to item Cite

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.

Journal Article J Manag Care Spec Pharm · July 2023 BACKGROUND: Niraparib is a highly selective poly (adenosine diphosphateribose) polymerase-1 and poly (adenosine diphosphate-ribose) polymerase-2 inhibitor indicated for select patients with ovarian, fallopian tube, and primary peritoneal cancer. The phase ... Full text Link to item Cite

Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: genitourinary cancer.

Journal Article Clin Adv Hematol Oncol · July 2023 Link to item Cite

Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.

Journal Article Clinical genitourinary cancer · June 2023 BackgroundTo characterize the impact of concomitant prostate cancer treatments with the use of relugolix, the oral GnRH receptor antagonist, in advanced prostate cancer, a subgroup and pharmacokinetic/pharmacodynamic analyses of the HERO study was ... Full text Cite

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer.

Journal Article EClinicalMedicine · June 2023 BACKGROUND: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in the phase 3 AL ... Full text Link to item Cite

PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.

Journal Article Clin Cancer Res · May 15, 2023 PURPOSE: In men with metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has drastically improved clinical outcomes. A liquid biopsy characterizing PSMA expression could be useful ... Full text Link to item Cite

How Do We Celebrate—and Survive— Increasing Survival?

Journal Article Clinical Advances in Hematology and Oncology · May 1, 2023 Cite

Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.

Journal Article JCO Oncol Pract · April 2023 PURPOSE: The implications of high prices for cancer drugs on health care costs and patients' financial burdens are a growing concern. Patients with metastatic castrate-resistant prostate cancer (mCRPC) are often candidates for multiple first-line systemic ... Full text Link to item Cite

Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.

Journal Article Cancer Med · March 2023 BACKGROUND: Understanding how patients perceive the efficacy, safety, and administrative burden of treatments for metastatic castration-resistant prostate cancer (mCRPC) can facilitate shared-decision making for optimal management. This study sought to eli ... Full text Link to item Cite

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.

Journal Article Eur Urol · March 2023 BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impac ... Full text Link to item Cite

Clinical Research Under Siege

Journal Article Clinical Advances in Hematology and Oncology · March 1, 2023 Cite

Rewiring of the N-Glycome with prostate cancer progression and therapy resistance.

Journal Article NPJ Precis Oncol · February 24, 2023 An understanding of the molecular features associated with prostate cancer progression (PCa) and resistance to hormonal therapy is crucial for the identification of new targets that can be utilized to treat advanced disease and prolong patient survival. Th ... Full text Link to item Cite

The Value of Phenotypic Precision Medicine in Prostate Cancer.

Journal Article Oncologist · February 8, 2023 Prostate cancer is the most common cancer among men and the second leading cause of cancer-related death. For patients who develop metastatic disease, tissue-based and circulating-tumor-based molecular and genomic biomarkers have emerged as a means of impr ... Full text Link to item Cite

End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.

Journal Article JCO Oncol Pract · February 2023 PURPOSE: New therapies including oral anticancer agents (OAAs) have improved outcomes for patients with metastatic renal cell carcinoma (mRCC). However, little is known about the quality of end-of-life (EOL) care and systemic therapy use at EOL in patients ... Full text Link to item Cite

Clear Cell Renal Cell Carcinoma: From Biology to Treatment.

Journal Article Cancers (Basel) · January 21, 2023 The majority of kidney cancers are detected incidentally and typically diagnosed at a localized stage, however, the development of regional or distant disease occurs in one-third of patients. Over 90% of kidney tumors are renal cell carcinomas, of which, c ... Full text Link to item Cite

How We Win Against Cancer

Journal Article Clinical Advances in Hematology and Oncology · January 1, 2023 Cite

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.

Journal Article Clin Cancer Res · November 14, 2022 PURPOSE: To evaluate AZD4635, an adenosine A2A receptor antagonist, as monotherapy or in combination with durvalumab in patients with advanced solid tumors. PATIENTS AND METHODS: In phase Ia (dose escalation), patients had relapsed/refractory solid tumors; ... Full text Link to item Cite

Racial disparities in Black men with prostate cancer: A literature review.

Journal Article Cancer · November 1, 2022 Black men are disproportionately affected by prostate cancer (PCa), with earlier presentation, more aggressive disease, and higher mortality rates versus White men. Furthermore, Black men have less access to PCa treatment and experience longer delays betwe ... Full text Link to item Cite

Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancer.

Journal Article BJUI Compass · November 2022 CONTEXT: Second-generation androgen receptor inhibitors (ARIs) extend metastasis-free survival, prolong overall survival, and delay symptoms when added to androgen deprivation therapy for the treatment of castration-sensitive or castration-resistant prosta ... Full text Link to item Cite

IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer.

Journal Article JCO Glob Oncol · November 2022 PURPOSE: To describe a newly established international registry recruiting diverse patients with advanced prostate cancer across academic and community practices to address unmet needs in this population. PATIENTS AND METHODS: Initiated in 2017, IRONMAN (I ... Full text Link to item Cite

Computational Faith

Journal Article Clinical Advances in Hematology and Oncology · November 1, 2022 Cite

Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?

Journal Article Future Oncol · October 13, 2022 WHAT IS THIS SUMMARY ABOUT?: This is a summary of a research article originally published in Prostate Cancer and Prostatic Diseases. There were few Black men in the clinical trials that led to the approval of the medications abiraterone and enzalutamide. A ... Full text Link to item Cite

Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.

Journal Article Nat Commun · October 10, 2022 Multigene assays can provide insight into key biological processes and prognostic information to guide development and selection of adjuvant cancer therapy. We report a comprehensive genomic and transcriptomic analysis of tumor samples from 171 patients at ... Full text Link to item Cite

Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.

Journal Article Clin Genitourin Cancer · October 2022 PURPOSE: In an era of rapid expansion of FDA approvals for oral anticancer agents (OAAs), it is important to understand the factors associated with survival among real-world populations, which include groups not well-represented in pivotal clinical trials ... Full text Link to item Cite

Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis.

Journal Article Biosens Bioelectron · October 1, 2022 Despite its high potential, PD-L1 expressed by tumors has not been successfully utilized as a biomarker for estimating treatment responses to immunotherapy. Circulating tumor cells (CTCs) and tumor-derived exosomes that express PD-L1 can potentially be use ... Full text Link to item Cite

Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).

Journal Article Urology · October 2022 OBJECTIVE: To examine real-world adherence to oral anticancer agents (OAAs) and its association with outcomes among Medicare beneficiaries with metastatic renal cell carcinoma (mRCC). METHODS: SEER-Medicare retrospective cohort study of patients with metas ... Full text Link to item Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.

Journal Article J Immunother Cancer · October 2022 BACKGROUND: Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of response are lacking to predict patients who will have a favorable or unfavorable res ... Full text Open Access Link to item Cite

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.

Journal Article BMJ Open · September 14, 2022 OBJECTIVES: The non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this modifica ... Full text Link to item Cite

Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.

Conference Prostate Cancer Prostatic Dis · September 2022 BACKGROUND: Prostate cancer is a clinically and molecularly heterogeneous disease, with highest incidence and mortality among men of African ancestry. To date, prostate cancer patient-derived xenograft (PCPDX) models to study this disease have been difficu ... Full text Open Access Link to item Cite

Racial disparities in prostate cancer among black men: epidemiology and outcomes.

Journal Article Prostate Cancer Prostatic Dis · September 2022 Prostate cancer has the widest racial disparities of any cancer, and these disparities appear at every stage of the cancer continuum. This review focuses on the disparities in prostate cancer between Black and White men, spanning from prevention and screen ... Full text Link to item Cite

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · September 2022 BACKGROUND: Black men are more likely to be diagnosed with aggressive prostate cancer (PC) and die from PC than white men. However, black men with metastatic castration-resistant PC (mCRPC) had longer overall survival (OS) than white men when treated with ... Full text Link to item Cite

Degriefing

Journal Article Clinical Advances in Hematology and Oncology · September 1, 2022 Cite

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.

Journal Article Cancers (Basel) · August 7, 2022 A lower baseline neutrophil-to-eosinophil ratio (NER) has been associated with improved responses to immune checkpoint inhibitors (ICI)-treated metastatic renal cell carcinoma (mRCC). This study investigated the decrease in NER at week 6 after ipilimumab/n ... Full text Link to item Cite

Rewiring of the N-Glycome with Prostate Cancer Progression and Therapy Resistance

Preprint · July 20, 2022 Full text Cite

Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).

Journal Article Clin Cancer Res · July 1, 2022 PURPOSE: CALGB 90206 was a phase III trial of 732 patients with metastatic renal cell carcinoma (mRCC) comparing bevacizumab plus IFNα (BEV + IFN) with IFNα alone (IFN). No difference in overall survival (OS) was observed. Baseline samples were analyzed to ... Full text Link to item Cite

Divide and Conquer, Cancer

Journal Article Clinical Advances in Hematology and Oncology · July 1, 2022 Cite

Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.

Journal Article J Geriatr Oncol · June 2022 INTRODUCTION: Oral anti-neoplastic agents (OAAs) for metastatic renal cell carcinoma (mRCC) are associated with increased cancer-specific survival. However, racial disparities in survival persist and older adults have the lowest rates of cancer-specific su ... Full text Link to item Cite

Setting a new standard for long-term survival in metastatic kidney cancer.

Journal Article Cancer · June 1, 2022 Full text Link to item Cite

Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.

Journal Article Adv Ther · June 2022 INTRODUCTION: We previously demonstrated that real-world progression (rwP) can be ascertained from unstructured electronic health record (EHR)-derived documents using a novel abstraction approach for patients with advanced non-small cell lung cancer (base ... Full text Link to item Cite

Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.

Journal Article Prostate · May 2022 BACKGROUND: In preclinical models of prostate cancer (PC), disulfiram (DSF) reduced tumor growth only when co-administered with copper (Cu), and Cu uptake in tumors is partially regulated by androgen-receptor signaling. However, prior trials of DSF in PC u ... Full text Link to item Cite

Back Together: Rebuilding Our Professional Culture

Journal Article Clinical Advances in Hematology and Oncology · May 1, 2022 Cite

Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.

Journal Article Prostate Cancer Prostatic Dis · April 2022 Full text Link to item Cite

Establishing metastatic prostate cancer quality indicators using a modified Delphi approach.

Journal Article Clin Genitourin Cancer · April 2022 BACKGROUND: There is variation in the care provided to men with metastatic prostate cancer (mPCa). There has been no previous set of quality indicators (QIs) regarding the management of men with mPCa. The objective of this study is to develop a set of inte ... Full text Link to item Cite

A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · April 2022 BACKGROUND: Men with progressive neuroendocrine or aggressive-variant metastatic prostate cancer (NEPC/AVPC) have a poor prognosis and limited treatment options, and immunotherapy has not been tested in such patients. METHODS: We conducted an open label si ... Full text Link to item Cite

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.

Journal Article Cancer · March 1, 2022 BACKGROUND: Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long-term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude patients with brain metastases, the ... Full text Link to item Cite

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

Journal Article Lancet Oncol · March 2022 BACKGROUND: Metastatic castration-resistant prostate cancers are enriched for DNA repair gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP proteins. We evaluated the anti-tumour activity and safety of the PARP in ... Full text Link to item Cite

A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).

Journal Article Prostate Cancer Prostatic Dis · March 2022 BACKGROUND: Androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSI) are associated with deleterious physical effects, which exercise may mitigate; however, exercise has never been studied in patients initiating treatment with A ... Full text Link to item Cite

Read My Lips

Journal Article Clinical Advances in Hematology and Oncology · March 1, 2022 Cite

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.

Journal Article Clin Genitourin Cancer · February 2022 INTRODUCTION: The Metastatic Renal Cell Carcinoma (MaRCC) Registry provides prospective data on real-world treatment patterns and outcomes in patients with metastatic renal cell carcinoma (mRCC). METHODS AND MATERIALS: Patients with mRCC and no prior syste ... Full text Link to item Cite

Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.

Journal Article Eur Urol Oncol · February 2022 CONTEXT: Prostate cancer (PCa) is a complex disease that disproportionately impacts Black men in the USA. The structural factors that drive heterogeneous outcomes for patients of differing backgrounds are probably the same ones that result in population-le ... Full text Link to item Cite

Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer.

Journal Article Oncogene · February 2022 Advanced and aggressive prostate cancer (PCa) depends on glutamine for survival and proliferation. We have previously shown that inhibition of glutaminase 1, which catalyzes the rate-limiting step of glutamine catabolism, achieves significant therapeutic e ... Full text Link to item Cite

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).

Journal Article Prostate Cancer Prostatic Dis · February 2022 BACKGROUND: The real-world EPIX study was conducted to gather information about the characteristics of patients with metastatic castration-resistant prostate cancer (mCRPC) who survived ≥2 years after treatment with the alpha-emitter radium-223. METHODS: T ... Full text Link to item Cite

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.

Journal Article J Immunother Cancer · February 2022 BACKGROUND: CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clinical features most ... Full text Link to item Cite

Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.

Journal Article Future Oncol · January 2022 Aim: To evaluate real-world clinical outcomes of radium-223 or alternative novel hormonal therapy (NHT) following first-line NHT for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: Retrospective analysis of the US Flatiron data ... Full text Link to item Cite

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer.

Journal Article Front Med (Lausanne) · 2022 Radium-223 dichloride (223Ra) is an α-emitter approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with bone metastases, but without visceral involvement. Despite being a life-prolonging therapy (LPT), 223Ra remains underut ... Full text Link to item Cite

The Search for the Optimal Immunotherapy Sequencing in the Perioperative Setting of RCC

Chapter · January 1, 2022 Based on the S-TRAC study, sunitinib was approved as adjuvant therapy for high-risk renal cell carcinoma after nephrectomy; however, the role of perioperative immunotherapy is less clear. Multiple immunotherapy combinations have shown clinical benefit supe ... Full text Cite

An Evolving Role for AXL in Metastatic Renal Cell Carcinoma.

Journal Article Clin Cancer Res · December 15, 2021 High tumoral expression of AXL was associated with inferior response to anti-PD-1 therapy and increased tumoral programmed death ligand 1 (PD-L1) expression in patients with metastatic renal cell carcinoma, with particularly poor outcomes in those with hig ... Full text Link to item Cite

Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.

Journal Article Eur Urol Oncol · December 2021 BACKGROUND: Salvage external beam radiotherapy (RT) with androgen deprivation therapy (ADT) improves survival over RT in men with prostate cancer (PC) and rising prostate-specific antigen (PSA) levels after radical prostatectomy (RP). OBJECTIVE: To investi ... Full text Link to item Cite

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.

Journal Article Prostate Cancer Prostatic Dis · December 2021 OBJECTIVE: Evaluation of the comparative effectiveness of enzalutamide and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) is limited to meta-analyses of randomized trials that exclude patients with significant comorbid ... Full text Link to item Cite

Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.

Journal Article JCO Oncol Pract · December 2021 PURPOSE: Availability of targeted oral anticancer agents (OAAs) has transformed care for patients with metastatic renal cell carcinoma (mRCC). Our objective was to identify patterns and predictors of OAA use within 12 months after mRCC was detected to unde ... Full text Link to item Cite

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Journal Article Eur Urol Open Sci · December 2021 BACKGROUND: Phase 2 trial endpoints that can be utilized in high-risk biochemical recurrence (BCR) after prostatectomy as a way of more rapidly identifying treatments for phase 3 trials are urgently needed. The efficacy of abiraterone acetate plus predniso ... Full text Link to item Cite

Nursing help wanted

Journal Article Clinical Advances in Hematology and Oncology · December 1, 2021 Cite

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.

Journal Article Biomark Res · November 3, 2021 BACKGROUND: The identification of biomarkers to select patients with metastatic renal cell carcinoma (mRCC) most likely to respond to combination immunotherapy (IO) is needed. We sought to investigate an association of the baseline neutrophil-to-eosinophil ... Full text Link to item Cite

Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.

Journal Article Future Oncol · November 2021 Androgen deprivation therapy using gonadotropin-releasing hormone (GnRH) analogues is standard treatment for intermediate and advanced prostate cancer. GnRH agonist therapy results in an initial testosterone flare, and increased metabolic and cardiovascula ... Full text Link to item Cite

Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)Androgen deprivation therapy (ADT) and radiotherapy (RT) are synergistic, and the combination results in improved survival outcomes for aggressive prostate cancers. However, long-term ADT carries substantial burden of toxicity ... Full text Cite

Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.

Journal Article J Clin Oncol · October 1, 2021 PURPOSE: To evaluate the safety and efficacy of gemcitabine and cisplatin in combination with the immune checkpoint inhibitor pembrolizumab as neoadjuvant therapy before radical cystectomy (RC) in muscle-invasive bladder cancer. METHODS: Patients with clin ... Full text Link to item Cite

Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.

Journal Article Cancer Med · October 2021 BACKGROUND: Improving oral anticancer agent (OAA) initiation and adherence is the important quality-of-care issues, particularly since one fourth of anticancer agents being developed will be administered orally. Our objective was to identify provider- and ... Full text Link to item Cite

Addressing the racial gap in health care

Journal Article Clinical Advances in Hematology and Oncology · October 1, 2021 Cite

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.

Journal Article BMC Cancer · September 15, 2021 Full text Link to item Cite

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.

Journal Article J Immunother Cancer · September 2021 The combination of ipilimumab plus nivolumab (I+N) has greatly improved outcomes in patients with intermediate or poor-risk untreated metastatic renal cell carcinoma (mRCC). However, little is known about the outcomes of patients with brain metastasis (BrM ... Full text Link to item Cite

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.

Conference BMC Cancer · August 7, 2021 BACKGROUND: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC after prior antiangiogenic therapy. METHODS: In this exploratory analysis, plasma bioma ... Full text Link to item Cite

A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.

Journal Article Cancer · August 2021 BackgroundRetrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus pr ... Full text Cite

Information “technoncology”

Journal Article Clinical Advances in Hematology and Oncology · August 1, 2021 Cite

Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.

Journal Article Clin Cancer Res · July 15, 2021 PURPOSE: While the detection of AR-V7 in circulating tumor cells (CTC) is associated with resistance to abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), it only accounts for a minority of this resistance. Neu ... Full text Link to item Cite

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).

Journal Article Cancer · July 1, 2021 BACKGROUND: Systemic therapy (ST) can be deferred in patients who have metastatic renal cell carcinoma (mRCC) and slow-growing metastases. Currently, this subset of patients managed with active surveillance (AS) is not well described in the literature. MET ... Full text Open Access Link to item Cite

Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.

Journal Article Clin Cancer Res · June 15, 2021 PURPOSE: Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC) to inform treatment selection but also to identify novel therapeutic targets. We thus sought to profile circulating angiokines in the context of a randomized trea ... Full text Link to item Cite

Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.

Journal Article Clin Cancer Res · June 15, 2021 Full text Link to item Cite

Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.

Conference Mol Cancer Res · June 2021 Men with circulating tumor cell (CTC) AR-V7-positive metastatic castration-resistant prostate cancer (mCRPC) have worse outcomes when treated with enzalutamide/abiraterone. However, most men lack CTC AR-V7 detection, and additional predictive biomarkers ar ... Full text Link to item Cite

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

Journal Article Eur J Cancer · June 2021 PURPOSE: To evaluate the prognostic significance of circulating tumour cell (CTC) number determined on the Epic Sciences platform in men with metastatic castration-resistant prostate cancer (mCRPC) treated with an androgen receptor signalling inhibitor (AR ... Full text Link to item Cite

Differential alternative RNA splicing and transcription events between tumors from African American and White patients in The Cancer Genome Atlas.

Journal Article Genomics · May 2021 Individuals of African ancestry suffer disproportionally from higher incidence, aggressiveness, and mortality for particular cancers. This disparity likely results from an interplay among differences in multiple determinants of health, including difference ... Full text Link to item Cite

Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.

Journal Article Int J Radiat Oncol Biol Phys · April 1, 2021 PURPOSE: Long-term androgen-deprivation therapy (ADT) is the standard of care in combination with radiation therapy (RT) in high-risk prostate cancer (PC), despite substantial toxicity from the resulting hypogonadism. We hypothesized that a combination of ... Full text Link to item Cite

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.

Journal Article J Clin Oncol · April 1, 2021 Full text Link to item Cite

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

Journal Article Cancer Med · April 2021 INTRODUCTION: Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA-approved as front-line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off-protocol and post-front-line expe ... Full text Link to item Cite

Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry.

Journal Article JCO Glob Oncol · April 2021 Prostate cancer disproportionately affects racial and ethnic minority populations. Reasons for disparate outcomes among minority patients are multifaceted and complex, involving factors at the patient, provider, and system levels. Although advancements in ... Full text Link to item Cite

Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.

Journal Article Nat Med · April 2021 Full text Link to item Cite

The new normal

Journal Article Clinical Advances in Hematology and Oncology · April 1, 2021 Cite

A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer.

Journal Article Proc Natl Acad Sci U S A · March 30, 2021 Cellular metabolism in cancer is significantly altered to support the uncontrolled tumor growth. How metabolic alterations contribute to hormonal therapy resistance and disease progression in prostate cancer (PCa) remains poorly understood. Here we report ... Full text Link to item Cite

Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.

Journal Article Pharm Stat · March 2021 The estimand framework requires a precise definition of the clinical question of interest (the estimand) as different ways of accounting for "intercurrent" events post randomization may result in different scientific questions. The initiation of subsequent ... Full text Link to item Cite

An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).

Journal Article Oncologist · March 2021 We report a case using combination cabozantinib plus nivolumab to salvage disease control in a patient with refractory metastatic renal cell carcinoma. The patient had previously experienced disease progression from high-dose interleukin-2, sunitinib, pazo ... Full text Link to item Cite

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.

Journal Article J Immunother Cancer · March 2021 BACKGROUND: Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI). METHODS: We condu ... Full text Open Access Link to item Cite

Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy

Journal Article Current Problems in Cancer: Case Reports · March 1, 2021 Patients with metastatic renal cell carcinoma are often affected by metastases to the brain that result in significant complications as well as limitations in clinical trial participation. Early generation tyrosine-kinase inhibitor and immune checkpoint in ... Full text Cite

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.

Journal Article Lancet · February 20, 2021 BACKGROUND: MET (also known as hepatocyte growth factor receptor) signalling is a key driver of papillary renal cell carcinoma (PRCC). Given that no optimal therapy for metastatic PRCC exists, we aimed to compare an existing standard of care, sunitinib, wi ... Full text Link to item Cite

Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.

Journal Article Biomark Res · February 18, 2021 BACKGROUND: A subset of men with metastatic prostate cancer (mPC) responds to immune checkpoint inhibitors, and there is an unmet need to predict those most likely to benefit. We characterized circulating tumor cells (CTCs) for expression of immune checkpo ... Full text Link to item Cite

Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.

Journal Article Future oncology (London, England) · February 2021 Aim: To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Materials & methods: Patients received adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off) or placebo. The primary ... Full text Cite

A test of trust

Journal Article Clinical Advances in Hematology and Oncology · February 1, 2021 Cite

Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.

Conference J Gen Intern Med · January 2021 BACKGROUND: Implementation methods of risk-stratified cancer screening guidance throughout a health care system remains understudied. OBJECTIVE: Conduct a preliminary analysis of the implementation of a risk-stratified prostate cancer screening algorithm i ... Full text Link to item Cite

Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.

Journal Article Kidney Cancer · 2021 BACKGROUND: Substantial racial and socioeconomic disparities in metastatic RCC (mRCC) have persisted following the introduction of targeted oral anticancer agents (OAAs). The relationship between patient characteristics and OAA access and costs that may un ... Full text Link to item Cite

New approaches to first-line treatment of advanced renal cell carcinoma.

Journal Article Ther Adv Med Oncol · 2021 The treatment of patients with renal cell carcinoma (RCC) is evolving rapidly, with promising new regimens being developed and approved for patients with advanced disease, particularly the combination of tyrosine kinase inhibitors with immune checkpoint in ... Full text Link to item Cite

Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).

Journal Article Cancer · December 15, 2020 BACKGROUND: Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (CABOSUN) was a randomized, open-label, phase 2 trial evaluating first- ... Full text Link to item Cite

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · December 2020 BACKGROUND: In this study, we evaluated real-world data on radium-223 plus abiraterone/prednisone or enzalutamide. Previously, the ERA 223 trial (NCT02043678) demonstrated increased fracture risk with concurrent treatment with radium-223 and abiraterone pl ... Full text Link to item Cite

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.

Journal Article Clin Genitourin Cancer · December 2020 BACKGROUND: Immune checkpoint inhibitors are now standard of care for many patients with metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordanc ... Full text Link to item Cite

Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.

Journal Article JCO Oncol Pract · December 2020 Germline genetic testing is now routinely recommended for patients with prostate cancer (PCa) because of expanded guidelines and options for targeted treatments. However, integrating genetic testing into oncology and urology clinical workflows remains a ch ... Full text Link to item Cite

The year of living stressfully

Journal Article Clinical Advances in Hematology and Oncology · December 1, 2020 Cite

Novel therapies are changing treatment paradigms in metastatic prostate cancer.

Journal Article J Hematol Oncol · October 28, 2020 Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients w ... Full text Link to item Cite

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.

Journal Article Cancer · October 15, 2020 BACKGROUND: Inhibition of the programmed cell death protein 1 (PD-1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies. Bruton tyrosine kin ... Full text Open Access Link to item Cite

Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.

Journal Article Clin Cancer Res · September 15, 2020 PURPOSE: In the S-TRAC trial, adjuvant sunitinib improved disease-free survival (DFS) compared with placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence. This post hoc exploratory analysis investigated the neutrophil- ... Full text Link to item Cite

Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.

Journal Article Biosens Bioelectron · August 15, 2020 Sensitive detection of circulating tumor cells (CTCs) from patients' peripheral blood facilitates on-demand monitoring of tumor progression. However, clinically significant capture of renal cell carcinoma CTCs (RCC-CTCs) remains elusive due to their hetero ... Full text Link to item Cite

Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.

Journal Article Clin Genitourin Cancer · August 2020 BACKGROUND: Clinical trials have demonstrated the efficacy of several life-prolonging therapies for metastatic castration-resistant prostate cancer (mCRPC); however, real-world data on their use, survival effect, and safety are limited. Using electronic he ... Full text Link to item Cite

Feeling siloed

Journal Article Clinical Advances in Hematology and Oncology · August 1, 2020 Cite

Racial Disparity in Response to Prostate Cancer Systemic Therapies.

Journal Article Curr Oncol Rep · July 23, 2020 PURPOSE OF REVIEW: In this review, we aim to describe racial differences in response to treatment for metastatic castration-resistant prostate cancer (mCRPC). RECENT FINDINGS: Recent data suggests that, despite higher risk features, African Americans may r ... Full text Link to item Cite

Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions.

Journal Article Cancer Epidemiol Biomarkers Prev · July 2020 BACKGROUND: Although there are considerable racial and ethnic disparities in prostate cancer incidence and mortality in the United States and globally, clinical trials often do not reflect disease incidence across racial and ethnic subgroups. This study ai ... Full text Link to item Cite

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.

Journal Article Oncoimmunology · June 10, 2020 BACKGROUND: Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) in mRCC, but has shown minimal clinical utility an ... Full text Link to item Cite

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

Journal Article N Engl J Med · June 4, 2020 BACKGROUND: Injectable luteinizing hormone-releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and ... Full text Link to item Cite

Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.

Journal Article Bioorg Med Chem Lett · June 1, 2020 Disulfiram in conjunction with copper has been shown to be a potent anticancer agent. However, disulfiram's therapeutic potential in prostate cancer is hindered by off-target effects due to its reactive and nucleophilic thiol-containing component, diethyld ... Full text Link to item Cite

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.

Journal Article Adv Ther · May 2020 INTRODUCTION: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naïve metastatic castration-resistant PC (mCRPC) trea ... Full text Link to item Cite

Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.

Journal Article Genes Chromosomes Cancer · April 2020 Circulating tumor cell (CTC) and cell-free (cf) DNA-based genomic alterations are increasingly being used for clinical decision-making in oncology. However, the concordance and discordance between paired CTC and cfDNA genomic profiles remain largely unknow ... Full text Link to item Cite

Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Journal Article J Clin Oncol · April 1, 2020 Shortly before I was elected President of ASCO, I attended the 65th birthday party of a current patient. She had been diagnosed 10 years earlier with metastatic breast cancer and hadn't been sure she wanted to move forward with further treatment. With enco ... Full text Link to item Cite

Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.

Journal Article Urol Oncol · March 2020 BACKGROUND: Activation of the PI3K-Akt-mTOR signaling pathway is common in advanced castration resistant prostate cancer (CRPC), typically through PTEN loss. Preclinical studies suggest that Akt-driven CaP cells are genetically susceptible to mammalian tar ... Full text Link to item Cite

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.

Journal Article J Immunother Cancer · March 2020 BACKGROUND: Immune checkpoint inhibitors (ICIs) have expanded treatment options for metastatic renal cell carcinoma (mRCC); however, there are limited predictive biomarkers for response to ICIs in this indication, with programmed death-ligand 1 (PD-L1) sta ... Full text Link to item Cite

What can we learn from cancer disparities?

Journal Article Gastroenterology and Hepatology · March 1, 2020 Cite

What can we learn from cancer disparities?

Journal Article Clinical Advances in Hematology and Oncology · March 1, 2020 Cite

Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma.

Journal Article Future Oncol · February 2020 Until recently, the sole treatment for patients with nonmetastatic renal cell carcinoma (RCC) was nephrectomy followed by observation. As metastatic RCC (mRCC) remains largely incurable (5-year survival rate ∼12%), adjuvant treatment, with potential to pre ... Full text Link to item Cite

Can I Get a Multidisciplinary Consult, Please? Systemic Immunotherapy and the Timing of Cytoreductive Nephrectomy.

Journal Article Eur Urol Focus · January 15, 2020 Patient selection is critical to determine who benefits from initial cytoreductive nephrectomy and who benefits from initial systemic treatment. Cytoreductive nephrectomy can no longer be considered a one-size-fits-all approach. Multidisciplinary evaluatio ... Full text Link to item Cite

The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.

Journal Article Cancer Treat Res Commun · 2020 Since the approval of immunotherapy checkpoint inhibitors for first-line treatment of metastatic renal cell carcinoma, new and clinically relevant questions have emerged that ongoing clinical trials and trials in development will address. These questions i ... Full text Link to item Cite

The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.

Journal Article Cancer J · 2020 The primary treatment for localized renal cell carcinoma (RCC) is surgical resection with curative intent. Despite this, many patients, especially those with high-risk features, will develop recurrent or metastatic disease. Antiangiogenic therapies targeti ... Full text Link to item Cite

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.

Journal Article JCO Precis Oncol · 2020 PURPOSE: Androgen receptor splice variant 7 (AR-V7) detection in circulating tumor cells (CTCs) is associated with a low probability of response and short progression-free (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate ... Full text Link to item Cite

Our relationship-intensive field

Journal Article Clinical Advances in Hematology and Oncology · January 1, 2020 Cite

The other “c” word

Journal Article Clinical Advances in Hematology and Oncology · January 1, 2020 Cite

Planning for retirement

Journal Article Clinical Advances in Hematology and Oncology · January 1, 2020 Cite

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).

Journal Article J Immunother Cancer · December 20, 2019 The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibit ... Full text Link to item Cite

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.

Journal Article Prostate Cancer Prostatic Dis · December 2019 BACKGROUND: Sipuleucel-T is an autologous cellular immunotherapy that is FDA approved for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). The IMPACT registry trial demonstrated a 4.1 month survi ... Full text Link to item Cite

Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.

Journal Article Urol Oncol · November 2019 PURPOSE: Targeted inhibitors and immunotherapy have entered the treatment landscape of metastatic prostate cancer. Genomic testing may uncover which patients benefit most from these therapies. We report the clinical utility and benefits of FoundationOne te ... Full text Link to item Cite

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.

Journal Article Oncologist · November 2019 Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Car ... Full text Link to item Cite

Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.

Journal Article Prostate · November 2019 BACKGROUND: Docetaxel prednisone is a standard of care for men with metastatic castration-resistant prostate cancer (mCRPC), and plasma vascular endothelial growth factor (VEGF) levels are a poor prognostic factor in this population; therefore, we evaluate ... Full text Link to item Cite

A noble nobel

Journal Article Clinical Advances in Hematology and Oncology · November 1, 2019 Cite

PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

Journal Article Clin Cancer Res · October 15, 2019 PURPOSE: Programmed death-ligand 1 (PD-L1) status by IHC is prognostic in metastatic renal cell carcinoma (mRCC), and its role as a potential predictive biomarker is under investigation. Using tumor tissue from the METEOR (NCT01865747) and CABOSUN (NCT0183 ... Full text Link to item Cite

A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.

Journal Article Prostate Cancer Prostatic Dis · September 2019 PURPOSE: The objective of this study was to test a low-carbohydrate diet (LCD) plus walking to reduce androgen deprivation therapy (ADT)-induced metabolic disturbances. MATERIALS AND METHODS: This randomized multi-center trial of prostate cancer (PCa) pati ... Full text Open Access Link to item Cite

Counting stars

Journal Article Clinical Advances in Hematology and Oncology · September 1, 2019 Cite

Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.

Journal Article J Clin Oncol · August 20, 2019 Full text Link to item Cite

Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Journal Article Clin Genitourin Cancer · August 2019 BACKGROUND: Germline genetic testing increasingly identifies advanced prostate cancer (PCa) patients who are candidates for precision therapies. The Prostate Cancer Clinical Trials Consortium (PCCTC) established the Germline Genetics Working Group to provi ... Full text Link to item Cite

Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.

Journal Article Cancer Med · August 2019 BACKGROUND: Pembrolizumab is approved for patients with metastatic, microsatellite instability (MSI)-high or mismatch repair-deficient (dMMR) solid tumors. However, very few men with prostate cancer were included in these initial studies. METHODS: We perfo ... Full text Link to item Cite

Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set.

Journal Article JCO Clin Cancer Inform · August 2019 PURPOSE: Large, generalizable real-world data can enhance traditional clinical trial results. The current study evaluates reliability, clinical relevance, and large-scale feasibility for a previously documented method with which to characterize cancer prog ... Full text Link to item Cite

Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.

Journal Article Prostate · July 2019 BACKGROUND: Radium-223 improves survival and time to first symptomatic skeletal event in symptomatic bone predominant metastatic castrate-resistant prostate cancer (mCRPC). The imaging response to radium-223 has not been well characterized. METHODS: To des ... Full text Link to item Cite

Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.

Journal Article Clin Adv Hematol Oncol · July 2019 Link to item Cite

Caring for every patient, learning from every patient

Journal Article Clinical Advances in Hematology and Oncology · July 1, 2019 Cite

Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.

Journal Article BMC Cancer · June 7, 2019 BACKGROUND: Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite treatment availability, the ... Full text Link to item Cite

Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Journal Article Clin Genitourin Cancer · June 2019 The incidence of renal-cell carcinoma has been increasing each year, with nearly one third of new cases diagnosed at advanced or metastatic stage. The advent of targeted therapies for metastatic renal-cell carcinoma (mRCC) has underscored the need to subty ... Full text Link to item Cite

Prostate Cancer National Summit's Call to Action.

Journal Article Clin Genitourin Cancer · June 2019 Full text Link to item Cite

Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities.

Journal Article Clin Cancer Res · May 15, 2019 Studies of alternative RNA splicing (ARS) have the potential to provide an abundance of novel targets for development of new biomarkers and therapeutics in oncology, which will be necessary to improve outcomes for patients with cancer and mitigate cancer d ... Full text Link to item Cite

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

Journal Article J Clin Oncol · May 1, 2019 PURPOSE: Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen therapies, including abiraterone or enzalutamide. Given that previous repo ... Full text Link to item Cite

Outcomes

Journal Article Clinical Advances in Hematology and Oncology · May 1, 2019 Cite

Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.

Journal Article Am J Clin Oncol · April 2019 Bone metastases are common in men with metastatic castrate-resistant prostate cancer (mCRPC), occurring in 30% of patients within 2 years of castrate resistance and in >90% of patients over the disease course. There are 6 US Food and Drug Administration-ap ... Full text Link to item Cite

Highlights in Advanced Prostate Cancer from the 2019 ASCO Genitourinary Cancers Symposium: Commentary.

Journal Article Clin Adv Hematol Oncol · April 2019 Link to item Cite

Talk to me

Journal Article Clinical Advances in Hematology and Oncology · March 1, 2019 Cite

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

Journal Article Clin Cancer Res · February 15, 2019 PURPOSE: In the S-TRAC trial, adjuvant sunitinib prolonged disease-free survival (DFS) versus placebo in patients with loco-regional renal cell carcinoma at high risk of recurrence after nephrectomy. An exploratory analysis evaluated associations between S ... Full text Link to item Cite

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.

Journal Article J Clin Oncol · February 10, 2019 PURPOSE: Several studies have reported that among patients with localized prostate cancer, black men have a shorter overall survival (OS) time than white men, but few data exist for men with advanced prostate cancer. The primary goal of this analysis was t ... Full text Link to item Cite

Precision Medicine Approaches When Prostate Cancer Akts Up.

Journal Article Clin Cancer Res · February 1, 2019 Ipatasertib combined with abiraterone in PTEN-null prostate cancer improved progression-free survival in a randomized phase II study of patients with metastatic castration-resistant prostate cancer (mCRPC), providing clinical evidence of reciprocal activat ... Full text Link to item Cite

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.

Journal Article J Immunother Cancer · January 24, 2019 BACKGROUND: PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with a diffe ... Full text Link to item Cite

Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma.

Journal Article Front Oncol · 2019 Despite numerous therapeutic advances in renal cell carcinoma (RCC), little is known about patients' perspectives on cancer care. An international survey was conducted to identify points of frustration associated with cancer care reported by patients with ... Full text Link to item Cite

Clinical advances: Past and present

Journal Article Clinical Advances in Hematology and Oncology · January 1, 2019 Cite

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.

Journal Article PLoS One · 2019 BACKGROUND: Radium-223 is a targeted alpha-particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B-ALP). We hypothesized tha ... Full text Link to item Cite

Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival

Journal Article Kidney Cancer · January 1, 2019 Background: No studies have looked at comparative outcomes in the treatment of metastatic renal cell carcinoma (mRCC) between academic and community practice settings. Methods: We created a joint academic (ACAD) and community (COMM) retrospective registry ... Full text Cite

Cancer of the Kidney

Chapter · January 1, 2019 Renal cell carcinoma (RCC) accounts for approximately 4% of adult malignancies, including approximately 90% of primary renal tumors. RCC exists in sporadic and hereditary forms and is a clinically and pathologically heterogeneous disease. The WHO classific ... Full text Cite

Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma.

Journal Article Eur Urol · December 2018 Full text Link to item Cite

The promise of immunotherapy in genitourinary malignancies.

Journal Article Precis Clin Med · December 2018 A broad understanding of the tumor immune landscape has led to a revolution of immune checkpoint inhibitors in the treatment of multiple cancer types. In genitourinary malignancies, immune checkpoint inhibitors have improved outcomes for patients with meta ... Full text Link to item Cite

Information Transparency in the Drug Approval Process.

Journal Article JAMA Oncol · November 1, 2018 Full text Link to item Cite

Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].

Journal Article Eur J Cancer · November 2018 Full text Link to item Cite

Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.

Journal Article Clin Genitourin Cancer · October 2018 INTRODUCTION: Genomic events leading to activation of mechanistic target of rapamycin (mTOR) are common in renal cell carcinoma (RCC). Everolimus is an allosteric mTOR inhibitor with efficacy in metastatic RCC. We characterized the genomic profile of RCC t ... Full text Link to item Cite

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.

Journal Article Ann Oncol · October 1, 2018 BACKGROUND: Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy (hazard ratio 0.76; 95% confidence interval, 0.59-0.98; two-sided P = 0.03). We ... Full text Link to item Cite

PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials.

Conference Ann Oncol · October 2018 Full text Link to item Cite

EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC).

Conference Ann Oncol · October 2018 Full text Link to item Cite

Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial.

Conference Ann Oncol · October 2018 Full text Link to item Cite

Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.

Journal Article Angew Chem Int Ed Engl · September 24, 2018 A prodrug approach is presented to direct copper-dependent cytotoxicity to prostate cancer cells. The prochelator GGTDTC requires activation by γ-glutamyl transferase (GGT) to release the metal chelator diethyldithiocarbamate from a linker that masks its t ... Full text Link to item Cite

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.

Journal Article Br J Cancer · September 2018 BACKGROUND: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic ther ... Full text Link to item Cite

Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival.

Journal Article Carcinogenesis · July 3, 2018 Prostate cancer (PCa) is a clinically and molecularly heterogeneous disease, with variation in outcomes only partially predicted by grade and stage. Additional tools to distinguish indolent from aggressive disease are needed. Phenotypic characteristics of ... Full text Open Access Link to item Cite

Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer.

Conference CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION · July 1, 2018 Link to item Cite

Nutritional profiling reveals glutamine-utilizing transaminases as a metabolic vulnerability of TAZ/YAP-driven breast cancer cells

Conference CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION · July 1, 2018 Link to item Cite

Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).

Conference JOURNAL OF CLINICAL ONCOLOGY · June 20, 2018 Link to item Cite

Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.

Journal Article Clin Genitourin Cancer · June 2018 Full text Link to item Cite

Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · May 20, 2018 Full text Cite

Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.

Journal Article JAMA Oncol · May 1, 2018 IMPORTANCE: The androgen receptor inhibitor enzalutamide prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC). In controlled clinical studies, 0.5% (10 of 2051) of patients experienced seizure, but patients with a history o ... Full text Link to item Cite

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.

Journal Article Eur J Cancer · May 2018 BACKGROUND: The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor risk met the primary end-point of improving progression-free survival (PFS) as assesse ... Full text Link to item Cite

Platinum sensitivity in metastatic prostate cancer: does histology matter?

Journal Article Prostate Cancer Prostatic Dis · April 2018 BACKGROUND: Platinum-based chemotherapy is effective in men with neuroendocrine prostate cancer (NEPC), but it is unclear whether histology (adenocarcinoma vs. non-adenocarcinoma NEPC variants) is predictive of platinum sensitivity. Given that NEPC exists ... Full text Link to item Cite

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.

Journal Article Clin Cancer Res · April 1, 2018 Purpose: Adjuvant sunitinib therapy compared with placebo prolonged disease-free survival (DFS) in patients with locoregional high-risk renal cell carcinoma (RCC) in the S-TRAC trial (ClinicalTrials.gov number NCT00375674). A prospectively designed explora ... Full text Link to item Cite

A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).

Conference Journal of Clinical Oncology · February 20, 2018 TPS710 Background: The anti-PD-1 antibody nivolumab (nivo) improves overall survival (OS) in metastatic treatment refractory RCC and is generally tolerable. In 2017, there is no standard adjuvant therapy proven to increase OS ove ... Full text Cite

Clinical utility of Foundation One tissue molecular profiling in men with metastatic prostate cancer.

Conference Journal of Clinical Oncology · February 20, 2018 318 Background: In the era of precision medicine, significant effort has been placed on identifying clinically actionable molecular targets to aid in the treatment of metastatic prostate cancer (mPC). Recent data supports homolog ... Full text Cite

Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.

Conference Journal of Clinical Oncology · February 20, 2018 11 Background: Combined external beam radiotherapy (RT) and androgen deprivation therapy (ADT) improves survival over RT alone for high risk prostate cancer (PC). Long-term ADT use, currently recommended for high risk PC, also in ... Full text Cite

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.

Conference Journal of Clinical Oncology · February 20, 2018 582 Background: The randomized phase 2 CABOSUN trial (NCT01835158) compared cabozantinib (C) with sunitinib (S) as initial systemic therapy in patients (pts) with RCC of intermediate or poor risk. Compared with S, C improved both ... Full text Cite

Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis.

Conference Journal of Clinical Oncology · February 20, 2018 576 Background: In the phase III S-TRAC trial, adjuvant sunitinib (SU) prolonged disease-free survival (DFS) vs placebo (PBO) in patients with locoregional renal cell carcinoma at high risk of recurrence after nephrectomy (median ... Full text Cite

Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.

Conference Journal of Clinical Oncology · February 20, 2018 160 Background: Radium-223 is a targeted alpha therapy that improves survival in men with mCRPC. The biologic basis for radium-223 efficacy is not completely understood. We hypothesized that PC osteomimicry, a form of epithelial ... Full text Cite

Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer (mPC).

Conference Journal of Clinical Oncology · February 20, 2018 191 Background: Most immune checkpoint inhibitors have shown limited efficacy in unselected men with mPC, and there is limited understanding about which immune checkpoints (ICs) are relevant in mPC. We evaluated ICs on the cell s ... Full text Cite

Patterns of progression in bone and soft tissue following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · February 20, 2018 222 Background: Bone scans were not obtained in the phase 3 ALSYMPCA trial, and retrospective series have reported varying rates of development of new lesions and resolution of existing lesions, following treatment with Radium-22 ... Full text Cite

Patients perspectives on adjuvant therapy in renal cell carcinoma.

Conference Journal of Clinical Oncology · February 20, 2018 644 Background: At this point in time, there is no approved adjuvant therapy (AT) for renal cell carcinoma (RCC) . The discussion on AT is driven by the pending maturation of overall survival (OS) data for sunitinib in patients a ... Full text Cite

S-TRAC trial: Sensitivity analyses of disease-free survival (DFS).

Conference Journal of Clinical Oncology · February 20, 2018 633 Background: DFS has been frequently used as endpoint in the adjuvant setting and was the primary basis of approval for adjuvant cancer therapies. In S-TRAC, adjuvant sunitinib demonstrated a significant improvement of DFS vs. ... Full text Cite

Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.

Journal Article Target Oncol · February 2018 Immune checkpoint blockers have revolutionized cancer treatment in recent years. These agents are now approved for the treatment of several malignancies, including melanoma, squamous and non-squamous non-small cell lung cancer, renal cell carcinoma, urothe ... Full text Link to item Cite

How we treat brain metastases in metastatic renal cell carcinoma.

Journal Article Clin Adv Hematol Oncol · February 2018 Link to item Cite

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

Journal Article J Immunother Cancer · January 29, 2018 BACKGROUND: Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as these patients were ex ... Full text Open Access Link to item Cite

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.

Journal Article J Immunother Cancer · January 25, 2018 Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are needed to predict for treatment res ... Full text Open Access Link to item Cite

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Journal Article Eur Urol · January 2018 BACKGROUND: Adjuvant sunitinib significantly improved disease-free survival (DFS) versus placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.5 ... Full text Link to item Cite

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Journal Article Ann Oncol · January 1, 2018 Full text Link to item Cite

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Journal Article JCO Precis Oncol · 2018 PURPOSE: Advances in germline genetics, and related therapeutic opportunities, present new opportunities and challenges in prostate cancer. The Prostate Cancer Clinical Trials Consortium Germline Genetics Working Group was established to address genetic te ... Full text Link to item Cite

Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.

Journal Article Clin Genitourin Cancer · December 2017 Full text Open Access Link to item Cite

Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.

Journal Article Clin Adv Hematol Oncol · September 2017 Link to item Cite

Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer.

Journal Article Int J Cancer · August 15, 2017 Evidence suggests that cells with a stemness phenotype play a pivotal role in oncogenesis, and prostate cells exhibiting this phenotype have been identified. We used two genome-wide association study (GWAS) datasets of African descendants, from the Multiet ... Full text Link to item Cite

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

Conference Eur J Cancer · August 2017 BACKGROUND: Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. METHODS: This was a multisite single ar ... Full text Link to item Cite

Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.

Journal Article Oncogene · July 27, 2017 Despite the advances in the diagnosis and treatment of breast cancer, breast cancers still cause significant mortality. For some patients, especially those with triple-negative breast cancer, current treatments continue to be limited and ineffective. There ... Full text Link to item Cite

Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.

Journal Article Oncogene · July 27, 2017 This corrects the article DOI: 10.1038/onc.2016.394. ... Full text Link to item Cite

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward.

Journal Article Kidney Cancer · July 26, 2017 In 2017, there is no adjuvant systemic therapy proven to increase overall survival in non-metastatic renal cell carcinoma (RCC). The anti-PD-1 antibody nivolumab improves overall survival in metastatic treatment refractory RCC and is generally tolerable. M ... Full text Link to item Cite

Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.

Journal Article Urol Oncol · June 2017 PURPOSE: Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration-resistant prostate cancer (mCRPC) ... Full text Link to item Cite

Reply to B. Rini et al and S. Buti et al.

Journal Article J Clin Oncol · June 1, 2017 Full text Link to item Cite

Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.

Journal Article Cancer Invest · May 28, 2017 The Metastatic Renal Cell Cancer Registry, a large, nationally representative, prospective registry of patients with metastatic renal cell carcinoma (mRCC), aims to understand real-world treatment patterns and outcomes of patients with mRCC in routine clin ... Full text Link to item Cite

A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500.

Conference Journal of Clinical Oncology · May 20, 2017 TPS4599 Background: PRCC constitutes approximately 15% of RCC cases, and no standard of care exists for metastatic disease. Approved VEGF- and mTOR-directed therapies for clear cell RCC in metastatic PRCC (mPRCC) have generally b ... Full text Cite

How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?

Journal Article Oncology (Williston Park) · April 15, 2017 Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. These treatment sequelae are significantly bothersome to patients and challenging to address. Awareness of these complications is critical in order to properly couns ... Link to item Cite

Cabozantinib in genitourinary malignancies.

Journal Article Future Oncol · April 2017 Cabozantinib inhibits a variety of cellular receptors including VEGFR1-3, MET, AXL, RET, FLT3 and KIT. These signaling pathways have been shown to be important in genitourinary malignancies. Along its clinical development, it has shown most activity in adv ... Full text Link to item Cite

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.

Conference Prostate · March 2017 BACKGROUND: Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent a ... Full text Link to item Cite

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Journal Article Cancer Chemother Pharmacol · March 2017 PURPOSE: To define the maximum tolerated dose (MTD), recommended phase II dose (RPTD), and assess safety and tolerability for the combination of pazopanib plus TH-302, an investigational hypoxia-activated prodrug (HAP), in adult patients with advanced soli ... Full text Link to item Cite

Students' participation in collaborative research should be recognised.

Journal Article Int J Surg · March 2017 Full text Link to item Cite

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Journal Article J Clin Oncol · February 20, 2017 Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cabozanti ... Full text Link to item Cite

Safety of Nonsteroidal Anti-inflammatory Drugs in Major Gastrointestinal Surgery: A Prospective, Multicenter Cohort Study.

Journal Article World J Surg · January 2017 BACKGROUND: Significant safety concerns remain surrounding the use of nonsteroidal anti-inflammatory drugs (NSAIDs) following gastrointestinal surgery, leading to wide variation in their use. This study aimed to determine the safety profile of NSAIDs after ... Full text Link to item Cite

Mobile Health Applications in Patients With Metastatic Renal Cell Carcinoma

Journal Article Kidney Cancer Journal · 2017 Open Access Link to item Cite

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Journal Article N Engl J Med · December 8, 2016 BACKGROUND: Sunitinib, a vascular endothelial growth factor pathway inhibitor, is an effective treatment for metastatic renal-cell carcinoma. We sought to determine the efficacy and safety of sunitinib in patients with locoregional renal-cell carcinoma at ... Full text Link to item Cite

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.

Journal Article Urol Oncol · December 2016 BACKGROUND: This phase 1/2 study evaluated the dose-limiting toxicity and maximum tolerated dose of MLN2704, a humanized monoclonal antibody MLN591 targeting prostate-specific membrane antigen, linked to the maytansinoid DM1 in patients with progressive me ... Full text Link to item Cite

Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.

Journal Article Oncotarget · November 29, 2016 Intratumoral inoculation of viruses with tumor-selective cytotoxicity may induce cancer cell death and, thereby, shrink neoplastic lesions. It is unlikely, however, that viral tumor cell killing alone could produce meaningful, durable clinical responses, a ... Full text Link to item Cite

Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.

Journal Article Urol Oncol · November 2016 BACKGROUND: The therapeutic armamentarium for metastatic renal cell carcinoma has rapidly expanded over the past decade to include a number of anti-angiogenic therapies and more recently, an immunotherapy. Biomarkers in the peripheral circulation are easil ... Full text Link to item Cite

genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)

Conference Annals of Oncology · October 1, 2016 Full text Cite

CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial

Conference Annals of Oncology · October 1, 2016 Full text Cite

Influence of diabetes and congestive heart failure (CHF) on selection of first-line (1L) treatment for metastatic renal cell carcinoma (mRCC)

Conference Annals of Oncology · October 1, 2016 Full text Cite

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.

Journal Article Asian J Urol · October 2016 The treatment of metastatic renal cell carcinoma (RCC) and urothelial carcinoma (UC) remains a major challenge. Past research has implicated the immune system in tumor surveillance of both malignancies, leading to the application of immunotherapy agents fo ... Full text Link to item Cite

What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.

Journal Article Ther Adv Urol · August 2016 Prostate cancer is the most common cancer in men and the second most deadly. About one-third of patients with prostate cancer will develop metastatic disease. We discuss the six United States Food and Drug Administration (FDA) approved treatments for metas ... Full text Link to item Cite

Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?

Journal Article AJR Am J Roentgenol · July 2016 OBJECTIVE: The purpose of this study is to investigate the accuracy of multiparametric MRI with endorectal coil and Partin tables in predicting organ-confined (OC) prostate cancer in a contemporary cohort undergoing radical prostatectomy (RP) and to assess ... Full text Link to item Cite

Development of a Novel c-MET-Based CTC Detection Platform.

Journal Article Mol Cancer Res · June 2016 UNLABELLED: Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a fe ... Full text Open Access Link to item Cite

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.

Journal Article Prostate Cancer Prostatic Dis · June 2016 BACKGROUND: Contemporary therapies for metastatic castration-resistant prostate cancer (mCRPC) have shown survival improvements, which do not account for patient experience and health-related quality of life (HRQoL). METHODS: This literature review include ... Full text Link to item Cite

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Journal Article J Clin Oncol · April 20, 2016 PURPOSE: Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior Pro ... Full text Link to item Cite

Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas.

Journal Article Cancer Res · April 1, 2016 Oncogenic transformation may reprogram tumor metabolism and render cancer cells addicted to extracellular nutrients. Deprivation of these nutrients may therefore represent a therapeutic opportunity, but predicting which nutrients cancer cells become addict ... Full text Link to item Cite

A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.

Conference Prostate Cancer Prostatic Dis · March 2016 BACKGROUND: In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiother ... Full text Link to item Cite

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

Journal Article Lancet Oncol · March 2016 BACKGROUND: Non-clear cell renal cell carcinomas are histologically and genetically diverse kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We aimed to compare the mTOR inhibitor everolimus and the VEGF receptor inhi ... Full text Link to item Cite

Abstract B18: Development of novel therapeutic splice-switching oligonucleotides against aggressive prostate cancer in men of African descent

Conference Cancer Epidemiology, Biomarkers & Prevention · March 1, 2016 AbstractAfrican American (AA) men exhibit a nearly 2-fold higher incidence and 3-fold higher mortality rate from prostate cancer compared to Caucasian American (CA) men and disparities in tumor aggressivenes ... Full text Cite

Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.

Journal Article Clin Genitourin Cancer · February 2016 UNLABELLED: We conducted a retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data of men with prostate cancer. Among 34,727 patients, those who died of their prostate cancer had more hospice and outpatient use, less inpatient a ... Full text Link to item Cite

Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · January 10, 2016 275 Background: Docetaxel prednisone (DP) is a standard of care for men with metastatic castrate resistant prostate cancer (mCRPC) with median progression-free survival (PFS) of 4-6 months and overall survival (OS) of 19 months, ... Full text Cite

Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.

Conference Journal of Clinical Oncology · January 10, 2016 273 Background: VT-464 is an oral, CYP17-L inhibitor and non-clinically an antagonist of the AR and its variants associated with clinical resistance to enzalutamide (ENZ) and abiraterone (AA). The safety, tolerability and initial ... Full text Cite

Physician treatment selection in the prospective Metastatic Renal Cell Cancer (MaRCC) Registry.

Conference Journal of Clinical Oncology · January 10, 2016 563 Background: Clinical trials mRCC pts are different from real world pts, resulting in bias in the literature. The MaRCC Registry is designed to survey questions not asked in tri als, such as why physicians make certain managem ... Full text Cite

Front-line management patterns in the prospective metastatic renal cell cancer (MaRCC) registry.

Conference Journal of Clinical Oncology · January 10, 2016 617 Background: Over the past decade, seven agents were approved for metastatic renal cell carcinoma (mRCC) leading to a rapidly evolving clinical landscape. Clinical trials addressing treatment efficacy, sequencing, and other qu ... Full text Cite

Physician treatment selection in the prospective metastatic renal cell cancer (MaRCC) registry

Conference BJU INTERNATIONAL · December 1, 2015 Link to item Cite

Front-line management patterns in the prospective metastatic renal cell cancer (MaRCC) registry

Conference BJU INTERNATIONAL · December 1, 2015 Link to item Cite

The metastatic renal cell carcinoma (MaRCC) Registry: a prospective academic and community-based study of metastatic renal cell cancer patients

Conference BJU INTERNATIONAL · December 1, 2015 Link to item Cite

Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach.

Journal Article Eur Urol · November 2015 BACKGROUND: There are no universally monitored outcomes relevant to men with advanced prostate cancer, making it challenging to compare health outcomes between populations. OBJECTIVE: We sought to develop a standard set of outcomes relevant to men with adv ... Full text Link to item Cite

Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.

Journal Article J Oncol Pract · November 2015 PURPOSE: Although narrow eligibility criteria improve the internal validity of clinical trials, they may result in differences between study populations and real-world patients, threatening generalizability. Therefore, we evaluated whether patients treated ... Full text Link to item Cite

A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).

Journal Article EBioMedicine · November 2015 BACKGROUND: Prognosis associated with metastatic renal cell carcinoma (mRCC) can vary widely. METHODS: This study used pretreatment nephrectomy specimens from a randomized phase III trial. Expression levels of candidate genes were determined from archival ... Full text Link to item Cite

Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.

Journal Article Cancer Immunol Res · September 2015 Sipuleucel-T is an autologous cellular immunotherapy for asymptomatic/minimally symptomatic metastatic castrate-resistant prostate cancer (CRPC). After disease progression, control-arm patients on three double-blind, randomized phase III sipuleucel-T trial ... Full text Link to item Cite

Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.

Journal Article Clin Genitourin Cancer · August 2015 BACKGROUND: Abiraterone acetate (AA) has demonstrated improved outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). However, data are lacking on the effect of AA on subsequent efficacy of enzalutamide or docetaxel. PATIENTS AND MET ... Full text Link to item Cite

A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.

Journal Article Clin Genitourin Cancer · August 2015 BACKGROUND: Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), and sunitinib, an oral inhibitor of vascular endothelial growth factor (VEGF)/platelet-derived growth factor receptor tyrosine kinase signaling, have both been shown to prov ... Full text Link to item Cite

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).

Journal Article J Clin Oncol · July 20, 2015 PURPOSE: On the basis of evidence that resistance to vascular endothelial growth factor (VEGF) receptor inhibition is caused by hypoxia-driven residual VEGF and other proangiogenic factors, combinations of agents from these classes were hypothesized to imp ... Full text Link to item Cite

DEVELOPMENT OF A STANDARDIZED SET OF PATIENT-CENTERED OUTCOMES FOR ADVANCED PROSTATE CANCER: AN INTERNATIONAL EFFORT FOR A UNIFIED APPROACH

Journal Article ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY · July 1, 2015 Link to item Cite

Deferred systemic therapy in patients with metastatic renal cell carcinoma.

Journal Article Clin Genitourin Cancer · June 2015 BACKGROUND: With the advent of small-molecule "targeted" therapies, the prevailing treatment paradigm for metastatic renal cell carcinoma (mRCC) is that all patients who are able to tolerate systemic therapy should receive it. However, oncologists often de ... Full text Link to item Cite

Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.

Journal Article Clin J Oncol Nurs · June 2015 BACKGROUND: Sipuleucel-T, an autologous cellular immunotherapy, is approved for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first personalized treatment for prostate cancer to be manuf ... Full text Link to item Cite

The future of kidney cancer treatment.

Journal Article Clin Adv Hematol Oncol · June 2015 Link to item Cite

Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN)

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2015 Link to item Cite

Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies.

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2015 Link to item Cite

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.

Journal Article BMC Cancer · May 7, 2015 BACKGROUND: Radium-223 has been shown to improve overall survival in men with metastatic castration-resistant prostate cancer with symptomatic bone metastases. The bone scan response to radium-223 has only been described in one single center trial of 14 pa ... Full text Link to item Cite

Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.

Journal Article Expert Opin Pharmacother · April 2015 OBJECTIVE: Comparing prognostic factors for overall survival (OS) in community-practice metastatic renal cell carcinoma (mRCC) patients receiving second-line everolimus with those previously reported in clinical trials. RESEARCH DESIGN AND METHODS: Two sep ... Full text Link to item Cite

A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).

Journal Article Cancer Chemother Pharmacol · April 2015 PURPOSE: This 2-arm crossover study compared the relative bioavailability of two dovitinib (TKI258) formulations [anhydrate clinical service form (CSF) capsule and monohydrate final market image (FMI) tablet; Arm 1] and determined the effect of food on dov ... Full text Link to item Cite

Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.

Journal Article Expert Opin Pharmacother · March 2015 INTRODUCTION: Over the past decade, treatment options for men with metastatic castration-resistant prostate cancer (CRPC) have expanded with the addition of abiraterone acetate (AA), enzalutamide, sipuleucel-T, radium-223, docetaxel and cabazitaxel. The op ... Full text Link to item Cite

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

Journal Article Urol Oncol · March 2015 BACKGROUND: The presence of ≥5 circulating tumor cells (CTCs) is prognostic for shorter survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, some men have low CTCs despite widespread disease, suggesting heterogeneity in CT ... Full text Link to item Cite

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

Journal Article Eur Urol · February 2015 BACKGROUND: Pain negatively affects quality of life for cancer patients. Preliminary data in metastatic castration-resistant prostate cancer (mCRPC) suggested a benefit of the oral tyrosine kinase inhibitor cabozantinib to pain palliation. OBJECTIVE: Prosp ... Full text Link to item Cite

A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.

Journal Article Eur Urol · January 2015 CONTEXT: The introduction of novel molecular-targeted agents has revolutionised the management of patients with metastatic renal cell carcinoma (mRCC). However, uncertainties remain over sequential or simultaneous combination therapies. OBJECTIVE: To syste ... Full text Link to item Cite

Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?

Journal Article Int J Urol · December 2014 OBJECTIVES: To determine whether oncological outcomes are improved in prostate cancer patients by using a multidisciplinary strategy as compared with a standard clinic paradigm, and whether time to treatment is delayed when using a multidisciplinary approa ... Full text Link to item Cite

Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.

Journal Article Curr Med Res Opin · November 2014 BACKGROUND: Second-line targeted therapies for metastatic renal cell carcinoma (mRCC) include mammalian target of rapamycin (mTOR) inhibitors and tyrosine kinase inhibitors (TKIs). This study compares the effectiveness of these therapies in a multi-practic ... Full text Link to item Cite

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

Conference J Clin Oncol · October 20, 2014 PURPOSE: Cabozantinib (XL184), an oral inhibitor of multiple receptor tyrosine kinases such as MET and VEGFR2, was evaluated in a phase II nonrandomized expansion study in castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: Patients received ... Full text Link to item Cite

Copper signaling axis as a target for prostate cancer therapeutics.

Journal Article Cancer Res · October 15, 2014 Previously published reports indicate that serum copper levels are elevated in patients with prostate cancer and that increased copper uptake can be used as a means to image prostate tumors. It is unclear, however, to what extent copper is required for pro ... Full text Open Access Link to item Cite

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

Journal Article Lancet Oncol · October 2014 BACKGROUND: In the final analysis of the phase 3 COU-AA-301 study, abiraterone acetate plus prednisone significantly prolonged overall survival compared with prednisone alone in patients with metastatic castration-resistant prostate cancer progressing afte ... Full text Link to item Cite

The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.

Journal Article Cancer Chemother Pharmacol · October 2014 PURPOSE: This 2-arm, phase 1, crossover study compared the relative bioavailability of two dovitinib (TKI258) capsule formulations [anhydrate clinical service form (CSF) and monohydrate final market image (FMI); Arm 1] and determined the effect of food on ... Full text Link to item Cite

Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice.

Journal Article Med Oncol · September 2014 Insights into the experience of metastatic renal cell carcinoma (mRCC) patients are needed to optimize patient care. A retrospective, multicenter registry of mRCC patients treated at academic (Duke) and community (ACORN) practices was developed to fill thi ... Full text Link to item Cite

Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings.

Journal Article Clin Adv Hematol Oncol · September 2014 Link to item Cite

Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings

Journal Article Clinical Advances in Hematology and Oncology · September 1, 2014 Cite

Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.

Journal Article Clin Cancer Res · August 15, 2014 PURPOSE: Orteronel (TAK-700) is an investigational, nonsteroidal, oral, inhibitor of androgen synthesis with greater specificity for 17,20-lyase than for 17α-hydroxylase. We investigated orteronel without steroids in patients with nonmetastatic castration- ... Full text Link to item Cite

A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.

Journal Article Clin Genitourin Cancer · August 2014 BACKGROUND: Vatalanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), whereas everolimus inhibits mammalian target of rapamycin (mTOR). Combination therapy with VEGFR and mTOR inhibitors has not been well tol ... Full text Link to item Cite

Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial.

Journal Article Ann Surg · June 2014 OBJECTIVE: To compare efficacy and safety of thromboprophylaxis with semuloparin started postoperatively versus enoxaparin started preoperatively in major abdominal surgery. BACKGROUND: Venous thromboembolism is an important complication following major ab ... Full text Link to item Cite

Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.

Conference Journal of Clinical Oncology · May 20, 2014 Full text Cite

Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.

Conference Journal of Clinical Oncology · May 20, 2014 Full text Cite

Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · May 20, 2014 Full text Cite

Clinical trial subjects compared to "real world" patients: Generalizability of renal cell carcinoma trials.

Conference Journal of Clinical Oncology · May 20, 2014 Full text Cite

Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.

Journal Article Cancer Chemother Pharmacol · May 2014 PURPOSE: This study was conducted to evaluate potential pharmacokinetic interactions between docetaxel and atrasentan as part of a phase I/II clinical trial. METHODS: Patients with prostate cancer were treated with intravenous docetaxel (60-75 mg/m(2)) eve ... Full text Link to item Cite

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.

Journal Article Curr Med Res Opin · April 2014 OBJECTIVE: To compare outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus, temsirolimus, and sorafenib following initial treatment with a tyrosine kinase inhibitor (TKI) in community and academic practices throughout the US. ... Full text Link to item Cite

Highlights in advanced prostate cancer from the 2014 American Society of Clinical Oncology genitourinary cancers symposium: commentary.

Journal Article Clin Adv Hematol Oncol · April 2014 Link to item Cite

Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry.

Journal Article J Oncol Pract · March 2014 INTRODUCTION: As new therapeutics for metastatic renal cell carcinoma (mRCC) are quickly introduced to market, comparative randomized trial evidence guiding treatment decisions is lacking, especially in the second treatment exposure and beyond. As a demons ... Full text Link to item Cite

Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?

Journal Article Clin Adv Hematol Oncol · March 2014 Meaningful progress has been realized in the treatment of metastatic renal cell carcinoma with the recent approval of a number of new agents; more new agents are on the horizon. Despite the recent completion of many clinical trials that have changed or wil ... Link to item Cite

Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment.

Conference Journal of Clinical Oncology · February 1, 2014 178 Background: Serum alkaline phosphatase (AP) changes in men with metastatic prostate cancer have been described since the Nobel Prize winning discovery of the hormonal dependence of PC. High serum AP is independently associate ... Full text Cite

Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings

Journal Article Clinical Advances in Hematology and Oncology · January 1, 2014 Cite

The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma.

Journal Article Urol Oncol · January 2014 OBJECTIVE: Gender-specific differences in incidence of renal cell carcinoma (RCC) and its outcome have previously been reported. We used age as a surrogate to test whether this might be hormone-related in a large international RCC cohort. METHODS AND MATER ... Full text Link to item Cite

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Journal Article Clin Genitourin Cancer · December 2013 BACKGROUND: Phosphatase and tensin homologue (PTEN) loss is common in advanced prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus blocks mammalian target of rapamycin (mTOR)/target of rapamycin complex 1 (TORC1), a ... Full text Link to item Cite

"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.

Journal Article Clin Genitourin Cancer · December 2013 BACKGROUND: New targeted therapeutics approved for metastatic renal cell carcinoma (mRCC) offer multiple options in each line of therapy; however, there are few prospective data beyond the first-line settings, and overall comparative effectiveness data are ... Full text Link to item Cite

Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success.

Journal Article Radiology · December 2013 PURPOSE: To determine the rate at which computed tomographically guided pelvic percutaneous bone biopsy in men with metastatic castration-resistant prostate cancer (mCRPC) yields adequate tissue for genomic profiling and to identify issues likely to affect ... Full text Link to item Cite

Survival following initiation of everolimus for 2nd-line treatment of metastatic renal cell carcinoma: prognostic factors in clinical practice and comparison to clinical trials

Conference BJU INTERNATIONAL · November 1, 2013 Link to item Cite

Comparative effectiveness of 2nd-line targeted therapies for metastatic renal cell carcinoma: analysis of two practice-based chart reviews

Conference BJU INTERNATIONAL · November 1, 2013 Link to item Cite

Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302.

Journal Article Molecular Cancer Therapeutics · November 1, 2013 AbstractBackground: Preclinical data demonstrate anti-VEGF agents can induce hypoxia, which may mediate resistance and induce increased tumor invasiveness. TH-302 is an investigational hypoxia-targeted drug; ... Full text Cite

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).

Journal Article Cancer · October 15, 2013 BACKGROUND: Preliminary data suggest a potential decreased benefit of docetaxel in patients with metastatic, castration-resistant prostate cancer (mCRPC) who previously received abiraterone acetate, a novel androgen synthesis inhibitor (ASI). Cancer and Le ... Full text Link to item Cite

Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.

Journal Article Urol Oncol · October 2013 OBJECTIVES: As complex novel cancer drugs are developed, supply may transiently fail to meet demand as production capacity established for research purposes is scaled up to meet anticipated clinical volume. There are no clear guidelines for how clinicians ... Full text Link to item Cite

Highlights in advanced prostate cancer from the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting: commentary.

Journal Article Clin Adv Hematol Oncol · September 2013 Link to item Cite

Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.

Journal Article J Oncol Pract · September 2013 PURPOSE: Contemporary tumor-directed therapies for metastatic castration-resistant prostate cancer (mCRPC) are approved to prolong life, but their effects on symptoms such as pain are less well understood as a result of the lack of analytically valid asses ... Full text Link to item Cite